Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$428.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 166.24% year-over-year to -$428.9 million in Q1 2026; TTM through Mar 2026 was -$1.7 billion, a 1177.53% decrease from a year earlier, with the FY2025 full-year figure at -$629.1 million, up 74.51% from the prior year.
• Cash from Investing Activities slipped to -$428.9 million in Q1 2026 per REGN's latest filing, from $220.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $647.5 million in Q1 2025 and bottomed at -$2.4 billion in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$428.9 million (2026), against an average of -$617.4 million.
• Biggest YoY gain for Cash from Investing Activities was 629.61% in 2024; the steepest drop was 615.78% in 2024.
• Year by year, Cash from Investing Activities stood at -$1.9 billion in 2022, then surged by 96.44% to -$66.2 million in 2023, then jumped by 629.61% to $350.6 million in 2024, then slumped by 37.16% to $220.3 million in 2025, then sank by 294.69% to -$428.9 million in 2026.
• Per Business Quant, the three latest REGN Cash from Investing Activities figures stand at -$428.9 million (Q1 2026), $220.3 million (Q4 2025), and -$402.9 million (Q3 2025).